Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (11-20 of 120) with videos related to

Pageof 12
Sort By:
Expert Opinion on Pharmacotherapy|March 3, 2016
Paliperidone for the treatment of schizoaffective disorderLarry Alphs, Dong-Jing Fu, Ibrahim Turkoz
Psychopharmacology Bulletin|August 26, 2017
Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform DisorderBrianne Brown, Larry Alphs, Ibrahim Turkoz, et al.
Schizophrenia Research|January 2, 2013
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorderGahan Pandina, Robert Bilder, Ibrahim Turkoz, et al.
Schizophrenia Research|February 4, 2018
A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthlyHugo Geerts, Athan Spiros, Patrick Roberts, et al.
Schizophrenia Research|January 9, 2016
A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophreniaLarry Alphs, Lian Mao, H Lynn Starr, et al.
Schizophrenia Research|November 5, 2002
Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicideSteven G Potkin, Ravi Anand, Larry Alphs, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2019
Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophreniaGurpreet Rekhi, Larry Alphs, Mei San Ang, et al.
Psychotherapy and Psychosomatics|December 7, 2023
The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric PropertiesGuy Chouinard, Fiammetta Cosci, Virginie-Anne Chouinard, et al.
The International Journal of Neuropsychopharmacology|January 6, 2012
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?Larry Alphs, Fabrizio Benedetti, W Wolfgang Fleischhacker, et al.
Innovations in Clinical Neuroscience|May 26, 2016
The Direct and Indirect Effects of Paliperidone Extended-release on Depressive Symptoms in Schizoaffective Disorder: A Path AnalysisIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
Pageof 12

Showing results (11-20 of 120) with videos related to

Sort By:
Pageof 12
Expert Opinion on Pharmacotherapy|March 3, 2016
Paliperidone for the treatment of schizoaffective disorderLarry Alphs, Dong-Jing Fu, Ibrahim Turkoz
Psychopharmacology Bulletin|August 26, 2017
Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform DisorderBrianne Brown, Larry Alphs, Ibrahim Turkoz, et al.
Schizophrenia Research|January 2, 2013
Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorderGahan Pandina, Robert Bilder, Ibrahim Turkoz, et al.
Schizophrenia Research|February 4, 2018
A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthlyHugo Geerts, Athan Spiros, Patrick Roberts, et al.
Schizophrenia Research|January 9, 2016
A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophreniaLarry Alphs, Lian Mao, H Lynn Starr, et al.
Schizophrenia Research|November 5, 2002
Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicideSteven G Potkin, Ravi Anand, Larry Alphs, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 26, 2019
Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophreniaGurpreet Rekhi, Larry Alphs, Mei San Ang, et al.
Psychotherapy and Psychosomatics|December 7, 2023
The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric PropertiesGuy Chouinard, Fiammetta Cosci, Virginie-Anne Chouinard, et al.
The International Journal of Neuropsychopharmacology|January 6, 2012
Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?Larry Alphs, Fabrizio Benedetti, W Wolfgang Fleischhacker, et al.
Innovations in Clinical Neuroscience|May 26, 2016
The Direct and Indirect Effects of Paliperidone Extended-release on Depressive Symptoms in Schizoaffective Disorder: A Path AnalysisIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
Pageof 12